📊 Executive Summary
Key Highlights
- Current Status: Pre-Revenue ($0 ARR, $0 MRR)
- Year 1 Target (2027): $51M ARR | $4.25M MRR | 50K members
- Year 5 Target (2031): $4.752B ARR | $396M MRR | 2.5M members
- 5-Year Total Revenue: $10.26B
- 5-Year Total EBITDA: $6.156B (60% margins)
- ARR Growth: 93x from Year 1 to Year 5
- Capital Required: $30M total ($5M seed + $25M Series A in 2026)
- Profitability: Year 1 (immediate EBITDA positive)
$0
Current ARR
Pre-Revenue Status
$51M
Year 1 ARR Target
2027 Projection
$4.75B
Year 5 ARR Target
2031 Projection
93x
ARR Growth
Year 1 to Year 5
📈 5-Year ARR Projections
| Year | ARR | YoY Growth | Members | PMPM | EBITDA | Margin |
|---|---|---|---|---|---|---|
| 2027 (Year 1) | $51.0M | Launch | 50,000 | $85 | $30.6M | 60% |
| 2028 (Year 2) | $367.2M | +620% | 250,000 | $122.40 | $220.3M | 60% |
| 2029 (Year 3) | $1,874.4M | +410% | 1,000,000 | $156.20 | $1,124.4M | 60% |
| 2030 (Year 4) | $3,215.7M | +72% | 1,750,000 | $153.00 | $1,929.6M | 60% |
| 2031 (Year 5) | $4,752.0M | +48% | 2,500,000 | $190.00 | $2,851.2M | 60% |
| 5-Year Total | $10,260.3M | CAGR: 186% | - | - | $6,156.2M | 60% |
Key Insights: Explosive Growth Phase
- Phase 1 (Years 1-3): Explosive growth with +620% and +410% YoY increases
- Phase 2 (Years 4-5): Sustained high growth with +72% and +48% YoY
- Member Growth: 50K → 2.5M members (50x expansion)
- PMPM Growth: $85 → $190 (123% increase as customers adopt complete platform)
💰 5-Year MRR Projections
| Year | Average MRR | Annual Total | Members | PMPM | MRR Growth |
|---|---|---|---|---|---|
| 2027 | $4.25M | $51.0M | 50,000 | $85 | Launch |
| 2028 | $30.60M | $367.2M | 250,000 | $122.40 | +620% |
| 2029 | $156.20M | $1,874.4M | 1,000,000 | $156.20 | +410% |
| 2030 | $267.98M | $3,215.7M | 1,750,000 | $153.00 | +72% |
| 2031 | $396.00M | $4,752.0M | 2,500,000 | $190.00 | +48% |
MRR Milestones
- 📍 $1M MRR: Q3 2027 (Month 9)
- 📍 $10M MRR: Q1 2028 (End of Year 1)
- 📍 $100M MRR: Q2 2029 (Mid-Year 3)
- 📍 $396M Exit MRR: End of 2031 (Year 5)
🎯 Year 1 (2027) Revenue Breakdown
Revenue by Pricing Tier ($51M Total)
| Tier | Members | PMPM | Annual Revenue | % of Total |
|---|---|---|---|---|
| Tier 1 Only (Risk Assessment) | 10,000 | $30 | $3.6M | 7% |
| Tier 2 Only (Diagnostic AI) | 15,000 | $50 | $9.0M | 18% |
| Tier 4 (IoMT-RPM) | 10,000 | $40 | $4.8M | 9% |
| Tiers 1+2+4 Combo | 5,000 | $120 | $7.2M | 14% |
| Complete Platform (All 4 Tiers) | 10,000 | $220 | $26.4M | 52% |
| TOTAL | 50,000 | $85 | $51.0M | 100% |
Key Insight: Complete Platform Drives Revenue
- 20% of customers (10,000 on Complete Platform) generate 52% of revenue
- Land-and-expand strategy: Start at Tier 1 ($30 PMPM), grow to Complete Platform ($220 PMPM)
- Average customer journey: $360K → $1.2M → $2.4M ARR over 18-24 months
Quarterly Revenue Ramp (2027)
| Quarter | Quarterly Revenue | Run-Rate ARR | Cumulative Customers |
|---|---|---|---|
| Q1 2027 | $7.65M | $30.6M | ~10 |
| Q2 2027 | $10.20M | $40.8M | ~20 |
| Q3 2027 | $15.30M | $61.2M | ~35 |
| Q4 2027 | $17.85M | $71.4M | ~50 |
| Total 2027 | $51.00M | $51M ARR | 50 |
💎 Exceptional Profitability (60% EBITDA Margins)
60%
EBITDA Margin
Constant across all 5 years
$6.16B
5-Year EBITDA
On $10.26B revenue
Year 1
Profitable
$30.6M EBITDA in 2027
40%
OpEx Ratio
Best-in-class efficiency
Typical SaaS
15-25%
EBITDA Margin
5-7 years to profitability
🏆 Cardio AI
60%
EBITDA Margin
Year 1 profitability
Best-in-Class SaaS
25-35%
EBITDA Margin
2-4 years to profitability
Why 60% EBITDA Margins Are Achievable
- Zero Marginal Cost: AI platform scales infinitely without added compute costs per patient
- Automated Operations: Self-service onboarding, AI-powered support, minimal human intervention
- Lean Headcount: 75 FTEs (Year 1) → 520 FTEs (Year 5) despite 93x revenue growth
- Remote-First: No facilities costs, global talent pool, outsourced non-core functions
- Platform Leverage: Built once, scales to millions of patients with no rebuilding
Capital Structure
- $5M Seed Round (2026): Fund Year 1 operations and initial customer acquisition
- $25M Series A (2026): Scale operations, expand sales team, accelerate growth
- Total Capital: $30M to reach $10.26B in 5-year revenue
- Return on Investment: 205x ($6.156B EBITDA / $30M invested)
- Capital Efficiency: $342M revenue per $1M invested
📊 Unit Economics - World-Class Performance
| Year | Customers | ARR per Customer | LTV (5-year) | CAC | LTV:CAC | CAC Payback |
|---|---|---|---|---|---|---|
| 2027 | 50 | $1.02M | $4.90M | $82K | 60:1 | 1.6 months |
| 2028 | 250 | $1.47M | $5.50M | $147K | 37:1 | 2.0 months |
| 2029 | 1,000 | $1.87M | $6.20M | $200K | 31:1 | 2.1 months |
| 2030 | 1,750 | $1.84M | $6.50M | $343K | 19:1 | 3.7 months |
| 2031 | 2,500 | $1.90M | $7.00M | $507K | 14:1 | 5.3 months |
| Average | - | $1.62M | $6.02M | $256K | 32:1 | 3 months |
Industry Benchmark
3:1
LTV:CAC Ratio
Healthy is 3:1, Excellent is 5:1
🏆 Cardio AI
32:1
LTV:CAC Ratio
11x better than benchmark
Best-in-Class
5:1
LTV:CAC Ratio
Top 5% of SaaS companies
💰 Investment Implications
$38M
Current Valuation
$5M for 15% equity
$30M
Total Capital Required
$5M seed + $25M Series A
205x
ROIC
$6.156B EBITDA / $30M
840-1,710x
Expected Return
In 5 years at exit
Exit Valuation Scenarios (Year 5)
| Scenario | ARR Multiple | Valuation | Your 15% Stake | Return on $5M |
|---|---|---|---|---|
| Conservative | 6x ARR | $28.5B | $4.3B | 855x |
| Base Case | 9x ARR | $42.8B | $6.4B | 1,280x |
| Optimistic | 12x ARR | $57.0B | $8.6B | 1,710x |
Why This Multiple Range Is Justified
- 60% EBITDA Margins: 2x better than best-in-class SaaS commands premium multiples
- High Growth + Profitability: Year 5 has 48% growth + 60% EBITDA = 108 Rule of 40
- Market Leadership: 2.5M members, dominant position in $187B TAM
- Cash Generation: $5.5B+ cash by Year 5, strongest balance sheet in sector
- Healthcare SaaS Comparables: Trade at 4-12x ARR depending on growth and profitability
⏰ Investment Window Closing
The opportunity to invest at pre-revenue pricing ($38M valuation) closes in 6-9 months when first revenue drives valuation to $250-500M based on revenue multiples. This represents a potential 7-13x revaluation just by reaching Year 1 revenue targets.
🏆 Competitive Advantage
Cardio AI vs. Healthcare SaaS Industry
| Metric | Industry Average | Cardio AI | Advantage |
|---|---|---|---|
| EBITDA Margin | 15-25% | 60% | 2.4-4x better |
| Years to $100M ARR | 6-8 years | 2 years | 3-4x faster |
| Years to Profitability | 5-7 years | Year 1 | 5-7 years faster |
| Capital to $50M ARR | $50-100M | $30M | 1.7-3.3x more efficient |
| LTV:CAC Ratio | 3:1 to 5:1 | 32:1 | 6-11x better |
| CAC Payback | 12-18 months | 3 months | 4-6x faster |
| Revenue/Employee (Y5) | $300-500K | $9.14M | 18-30x better |
Why Cardio AI Outperforms
- Comprehensive Platform: 8 AI agents vs competitors' 1-2 solutions = 4-8x broader offering
- Zero Marginal Cost: Serving 2.5M patients costs same as 50K (AI scales infinitely)
- Premium Pricing: $85-190 PMPM vs $20-50 industry average = 1.7-3.8x higher pricing power
- Technology Leadership: 5-10 year head start, 6 agents validated, 95%+ accuracy proven
- Network Effects: More data → Better models → More customers → More data (flywheel)
📅 Revenue Timeline & Milestones
Q1 2026 (Current)
Status: Pre-Revenue ($0 ARR)
Beta program launches with 10 sites. Platform operational, 6 agents validated.
Q3 2026
Target: $1-2M ARR
First paying customer signed. Product-market fit validated. Beta conversions begin.
Q4 2026
Target: $2-5M ARR
2-5 customers signed. Sales model proven. Beta program completing.
2027 (Year 1)
Target: $51M ARR
50 customers, 50K members. $30.6M EBITDA (60% margin). Profitable from Day 1.
2028 (Year 2)
Target: $367M ARR (+620%)
250 customers, 250K members. Hyper-growth phase. Market validation complete.
2031 (Year 5)
Target: $4.752B ARR
2,500 customers, 2.5M members. $2.85B EBITDA. Market leadership established. IPO ready.